Central Nervous System Toxicity After Botulinum Neurotoxin Injection

Since Its first description of botulism toxicity in 1820s, specific formulations of botulinum neurotoxin (BoNT) have been introduced with different clinical benefits. However, there is increasing number of adverse events reported to Food and Drug Administration. This report presents the case of 62-year-old woman with Parkinson’s disease who received BoNT injections to treat painful spasticity in her hands. She developed severe generalized dystonia shortly after BoNT injections.

• Publication year

  2013

• Venue

  Anesthesiology and Pain Medicine

• Publication date

  2013-06-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.5812/aapm.9356PMID 24223367PMCID 3821148
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Flu-like symptoms following botulinum toxin therapy.

  2011cited by this paper
• Adverse effects of botulinum neurotoxin A in spasticity management

  2011cited by this paper
• Botulinum toxin—Beyond wrinkles

  2011cited by this paper
• Systemic Weakness After Therapeutic Injections of Botulinum Toxin A: A Case Series and Review of the Literature

  2010cited by this paper
• Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial

  2010cited by this paper
• A randomized controlled study of botulinum toxin A in the treatment of hemiplegic shoulder pain associated with spasticity

  2007cited by this paper
• Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.

  2005cited by this paper
• Neurobiological basis for the use of botulinum toxin in pain therapy

  2004cited by this paper
• Toxicity of botulinum neurotoxins in central nervous system of mice.

  2003cited by this paper
• A summary of spasticity management--a treatment algorithm.

  2002cited by this paper
• A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain

  2002cited by this paper
• A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke

  2000cited by this paper
• Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases.

  1997cited by this paper
• Response and immunoresistance to botulinum toxin injections

  1995cited by this paper
• Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25

  1993cited by this paper
• Therapeutic use of type F botulinum toxin.

  1992cited by this paper
• Clinical, Cosmetic and Investigational Dermatology Dovepress Botulinum Toxin Type a for the Management of Glabellar Rhytids

  year unknowncited by this paper

• Safety profile and side effects of botulinum toxin in neurological practice

  2025cites this paper
• Botulinum Neurotoxin Induces Neurotoxic Microglia Mediated by Exogenous Inflammatory Responses

  2024cites this paper
• Tirbanibulin (KX2‐391) analog KX2‐361 inhibits botulinum neurotoxin serotype A mediated SNAP‐25 cleavage in pre‐ and post‐intoxication models in cells

  2024cites this paper